Enlivex Therapeutics (NASDAQ:ENLV) Announces Earnings Results

Enlivex Therapeutics (NASDAQ:ENLV) posted its quarterly earnings results on Monday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.07), Zacks reports.

Enlivex Therapeutics Stock Down 1.4 %

NASDAQ ENLV traded down $0.01 during trading hours on Wednesday, hitting $0.94. The company had a trading volume of 28,763 shares, compared to its average volume of 154,250. Enlivex Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $4.59. The firm has a market cap of $20.06 million, a P/E ratio of -0.96 and a beta of 1.11. The business has a fifty day simple moving average of $1.09 and a 200-day simple moving average of $1.23.

Analyst Upgrades and Downgrades

ENLV has been the topic of a number of research reports. HC Wainwright increased their target price on shares of Enlivex Therapeutics from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, March 24th. D. Boral Capital reiterated a “buy” rating and set a $13.00 price objective on shares of Enlivex Therapeutics in a research note on Monday, March 3rd.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.